Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

News Conference News TCT 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

Todd Neale

October 25, 2023

News Conference News TCT 2020

Shorter DAPT Succeeds in Xience-Treated Patients at High Bleeding Risk

Caitlin E. Cox

October 15, 2020

News Conference News TCT 2019

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

Caitlin E. Cox

October 08, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

L.A. McKeown

September 26, 2019

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

News Conference News TCT 2018

EXCEL Deep Dive: Repeat Revascularization, Medical Therapy, and Anemia All Impact Patient Prognosis

Michael O'Riordan

September 21, 2018

News Conference News TCT 2017

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

Todd Neale

November 01, 2017

News Conference News TCT 2015

Intracoronary Brachytherapy Reduces DES ISR but Restenosis not Eliminated

October 12, 2015

News Conference News TCT 2015

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

October 12, 2015

Presentation TCT 2014

No: And Ill Show You Why!

Presenter: Sanjay Kaul, Ajay J. Kirtane, Joanna J. Wykrzykowska

September 13, 2014

Presentation TCT 2014

Yes: What is WORST is BEST!

Presenter: Sanjay Kaul, Ajay J. Kirtane, Christopher B. Granger

September 13, 2014

Presentation TCT 2013

No! Aspirin and Ticagrelor Is a Much Better Option

Presenter: Emmanouil Brilakis

October 28, 2013

News Conference News TCT 2013

COMFORTABLE AMI: Biolimus-Eluting Stent Bests BMS in STEMI

October 28, 2013

Advertisement

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

Shorter DAPT Succeeds in Xience-Treated Patients at High Bleeding Risk

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

EXCEL Deep Dive: Repeat Revascularization, Medical Therapy, and Anemia All Impact Patient Prognosis

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

Intracoronary Brachytherapy Reduces DES ISR but Restenosis not Eliminated

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

No: And Ill Show You Why!

Yes: What is WORST is BEST!

No! Aspirin and Ticagrelor Is a Much Better Option

COMFORTABLE AMI: Biolimus-Eluting Stent Bests BMS in STEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content